Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study

N Bhatia,H Baldwin,M Ahmadyar,J Del Rosso,H Hansra,Am Daniels

doi:10.25251/skin.2.supp.34

Abstract

Abstract not available. Disclosures: Study supported by BioPharmX, Inc. Copyright SKIN 2018

Highlights

Significant side effects such as gastrointestinal distress and vertigo may make long-term use of oral minocycline intolerable and chronic use may contribute to resistance
Its preliminary safety and efficacy profiles have been demonstrated in extensive preclinical testing
» 3 adverse events were reported, but none were related to the study drug or Percentagesotfusdubyjeactsssweitshsimmperonvetsments or no change in investigator- and subject-rate»d cLuotawneeorusmtoolelraanrcae bscsocrees sfrsom(nBa=s1el;in1e%to Week 12 arm)

Summary

Introduction

Chronic, and relapsing skin disorder that presents with a variety of clinical manifestations primarily on the central face[1]. The papulopustular subtype forms acne-like inflammatory papules, pustules, and plaques. Immune, inflammatory, vascular, and environmental mechanisms may contribute to its development[2,3]. Minocycline is effective as a first-line systemic therapy for rosacea; it is thought that, like other tetracyclines, its antiinflammatory properties are responsible[5]. Significant side effects such as gastrointestinal distress and vertigo may make long-term use of oral minocycline intolerable and chronic use may contribute to resistance. Another form of delivery with lower overall dosage and reduced systemic side effects is needed. » Low dose: 1% and 2% minocycline » Minimizes side effects » Low systemic exposure

Positive Patient Experience

Methods

Good Safety Profile